# Takeda and Lundbeck Call for Grant Application

<table>
<thead>
<tr>
<th>Date Issued</th>
<th>November 12, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deadline for Application</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Award(s) Announced</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Therapeutic Area</td>
<td>Major Depressive Disorder (MDD)</td>
</tr>
</tbody>
</table>

**Purpose of Call for Grant Application (CGA)**

The purpose of this CGA is to increase health care professional knowledge of evolving science related to:

- The role of the serotonergic system in MDD
- Acute and residual symptoms of MDD
- New and emerging pharmacologic treatments for MDD

**Summary of Health Care Gap**

Major depressive disorder (MDD) is a relatively common disorder associated with substantial morbidity, mortality and health care costs (1 - 7).

While the underlying pathophysiology has not been fully elucidated, essentially all currently available antidepressants affect brain monoamine systems (8 – 10). Only approximately 50% of patients respond reasonably well to treatment and only one third reach remission (11). In addition, short and long term tolerability remains suboptimal and can negatively influence patient adherence (12). Not all symptoms of depression are uniformly well recognized (e.g., cognitive symptoms) (13,14); and some may persist despite otherwise apparently adequate response (11,15). Patients with residual symptoms have poorer long term outcomes than do those who achieve remission (16,17).

Doubtless numerous neurochemical and electrophysiologic systems interact with each other in the pathogenesis of MDD (18). However, the ascending serotonergic projections from the mesencephalic raphe nuclei consistently appear to be involved (18). The serotonergic system, with its multiple receptor subtypes, is complex, as are its interactions with other neurochemical systems (18). Thus many "downstream" effects on other monoaminergic neurotransmitter systems may also play a role in the development of MDD (10,19).

**Potential learner**

Psychiatrists and/or primary care providers who treat patients with MDD

**Educational format**

Live scientific conferences, grand rounds or other local/regional educational activities occurring in 2013 that may or may not include online or other enduring components.

**Outcome measures**

At minimum, the educational evaluation plan must be designed to objectively measure improvements in HCP knowledge (Level 3) (20).

**Funding guide**

Multi or sole support
Submission Requirements

When responding to this CGA, please follow the established guidelines for the Takeda medical education grant submission process. All applications must be submitted online through www.takedaeducationalgrants.com.

The education must be accredited by the appropriate accrediting bodies, be fully compliant with ACCME criteria and the Standards for Commercial Support and must be in accordance with the U.S. Food and Drug Administration’s Guidance on Industry-Supported Scientific and Educational Activities. If accepted, must attest to the terms, conditions and purposes of an educational grant as described in the Takeda letter of agreement.

References

3. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of Major Depressive Disorder: Results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry. 2005;62(10):1097-1106.